Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208

Nov 21, 2022 | Press Releases

– RP1208 is in preclinical development for the potential treatment of depression and obesity – – Composition of matter patents for RP1208 have been granted in key markets around the world including the United States, Europe, China, and Japan –...

Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2022 Financial Results and Recent Business Highlights

Nov 14, 2022 | Press Releases

– Over 30% enrollment in ongoing global, pivotal Phase 3 RECOVER trial – – Topline data for Phase 3 RECOVER trial evaluating brilaroxazine for schizophrenia still expected mid-2023 – – $23.2 Million in Cash as of September 30, 2022...

Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia

Oct 31, 2022 | Press Releases

– Enrollment ongoing at multiple sites in the US and Europe; site initiation in Asia expected in November 2022 – – Enrollment on pace, with over 30% enrolled in the United States – – Topline data for RECOVER evaluating brilaroxazine for...

Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Oct 13, 2022 | Press Releases

CUPERTINO, CA / October 13, 2022 / Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH), (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...

Reviva Pharmaceuticals to Present at the Lytham Partners Fall 2022 Investor Conference

Sep 26, 2022 | Press Releases

CUPERTINO, Calif., Sept. 26, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...